Company intelligence / Profile preview

Proteimax Biotechnology

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a family of 54 peptides that modulate cannabinoid receptors. Their lead peptide, Pep19, has shown ability to promote loss of body fat, reduce liver fat, flatten glycemic spikes, and reduce fasting insulin.

Therapeutic areas: Metabolic DisordersEndocrinologyGastroenterology
Modalities: Peptides
Industry: Non-Drug Biotech

Drug pipeline

3 assets

Pep19

Pre-clinical

Indications: Obesity

2 more assets in the full pipeline.

Request access →

Partnerships

NutroslimSanval EnterpriseBINAmajor food corporations (unnamed)

Beyond the preview

Go deeper on Proteimax Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteimax Biotechnology.

Explore the full profile